
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is expected to see positive financial performance in the coming years due to its strong focus on immuno-oncology and its leading position in drug development in this area. The company's heavy investment in research and development, coupled with its judicious spending and management's expertise, are likely to drive growth and contribute to its revenue and earnings. The updated model shows positive trends in total revenue and EPS, with our PT reflecting expectations for higher revenue and earnings driven by the approval of Zenbexus and management's continued support of the growth portfolio.
Bears say
Bristol-Myers Squibb is facing the challenge of high dependence on the US market, which could expose the company to potential political and regulatory risks. Additionally, while the company has a strong focus on immuno-oncology and growth products, the expected declines in legacy products and evenly phased OpEx in 2026 could limit earnings growth. However, with a catalyst-rich 2026 and potential for multiple expansion opportunities with upcoming clinical readouts and label expansions, the company may see investor interest and potential for profitability in the long term.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares